<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01558869</url>
  </required_header>
  <id_info>
    <org_study_id>MONC-HBP24</org_study_id>
    <nct_id>NCT01558869</nct_id>
  </id_info>
  <brief_title>Xeloxiri as First-line Treatment in Patients With Advanced Unresectable Pancreatic Adenocarcinoma</brief_title>
  <official_title>An Open-label, Single-centre, Single-arm Phase II Study of Capecitabine Combined With Oxaliplatin and Irinotecan (Xeloxiri) as First-line Treatment in Patients With Advanced Unresectable Pancreatic Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Hong Kong</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, single centre, single-arm phase II study which aims to assess the&#xD;
      efficacy and tolerability of triplet combination of capecitabine, oxaliplatin and irinotecan&#xD;
      (Xeloxiri regimen) in treating patients with advanced unresectable pancreatic carcinoma.&#xD;
      Clinical data from patients diagnosed with pancreatic adenocarcinoma will be collected and&#xD;
      analyzed in this study. The patients' data will be collected and maintained in the Division&#xD;
      of Medical Oncology of the University Department of Medicine, Queen Mary Hospital, Hong Kong.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in extent of disease</measure>
    <time_frame>Change from baseline in size approximately every 4 cycles</time_frame>
    <description>Objective response rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CA19.9 reduction</measure>
    <time_frame>Change from baseline every 2 cycles</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>From date of start until the date of first documented progression or death from disease-related causes or last follow-up, whichever came first, assessed up to 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From date of start until the date of death from any cause or last follow-up, whichever came first, assessed up to 18 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Pancreatic Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>1200 mg/m2 BD orally for 1 week of a 2-week cycle (i.e. 1 week on, 1 week off)</description>
    <arm_group_label>Arm 1</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>70 mg/m2 IV on day 1 of a 2-week cycle</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>130 mg/m2 IV on day 1 of a 2-week cycle</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults ≥ 18 years of age, male or female.&#xD;
&#xD;
          -  Histopathologically or cytologically confirmed adenocarcinoma of the pancreas.&#xD;
&#xD;
          -  ECOG performance status 0 to 2.&#xD;
&#xD;
          -  Adequate bone marrow reserve.&#xD;
&#xD;
          -  Absolute neutrophil count &gt; 1x10^9/L.&#xD;
&#xD;
          -  Total bilirubin &lt;3 times the upper limit of the normal range.&#xD;
&#xD;
          -  Life expectancy ≥ 12 weeks.&#xD;
&#xD;
          -  Signed written informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior malignant disease other than pancreatic cancer.&#xD;
&#xD;
          -  Patients suitable for surgical or locoregional therapies.&#xD;
&#xD;
          -  Patients who have prior anticancer therapy for pancreatic cancer.&#xD;
&#xD;
          -  Patients unable to swallow oral medications.&#xD;
&#xD;
          -  Any evidence of brain metastasis (unless the patient is &gt;6 months from definitive&#xD;
             therapy, has a negative imaging study within 4 weeks of study entry and is clinically&#xD;
             stable with respect to the tumor at the time of study entry).&#xD;
&#xD;
          -  Active clinically serious infections (&gt; grade 2 NCI / CTC Adverse Event version 3.0).&#xD;
&#xD;
          -  History of allergy to platinum compounds.&#xD;
&#xD;
          -  Patients who have chronic inflammatory bowel disease and/or bowel obstruction.&#xD;
&#xD;
          -  Patients who have severe bone marrow failure.&#xD;
&#xD;
          -  Patients undergoing renal dialysis.&#xD;
&#xD;
          -  History of HIV infection.&#xD;
&#xD;
          -  Seizure disorder requiring medication (such as steroids or anti-epileptics).&#xD;
&#xD;
          -  Women who are pregnant or breast-feeding, or women of child-bearing potential who are&#xD;
             unable or unwilling to practice a highly effective means of contraception.&#xD;
&#xD;
          -  Substance abuse, medical, psychological or social conditions that may interfere with&#xD;
             the patient's participation in the study or evaluation of study results.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Yau, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Hong Kong</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Queen Mary Hospital, The University of Hong Kong</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <reference>
    <citation>Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardière C, Bennouna J, Bachet JB, Khemissa-Akouz F, Péré-Vergé D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M; Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011 May 12;364(19):1817-25. doi: 10.1056/NEJMoa1011923.</citation>
    <PMID>21561347</PMID>
  </reference>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>March 18, 2012</study_first_submitted>
  <study_first_submitted_qc>March 18, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2012</study_first_posted>
  <last_update_submitted>May 6, 2017</last_update_submitted>
  <last_update_submitted_qc>May 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Dr. YAU Chung Cheung Thomas</investigator_full_name>
    <investigator_title>Clinical Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

